GENERAL ENQUIRIES: Tel: + 27 12 841 2911 | Email: callcentre@csir.co.za

Show simple item record

dc.contributor.author Mallajosyula, JK
dc.contributor.author Hiatt, E
dc.contributor.author Hume, S
dc.contributor.author Johnson, A
dc.contributor.author Jeevan, T
dc.contributor.author Chikwamba, Rachel K
dc.contributor.author Pogue, GP
dc.contributor.author Bratcher
dc.contributor.author Haydon, H
dc.contributor.author Webby, RJ
dc.contributor.author McCormick, AA
dc.date.accessioned 2015-05-25T10:52:28Z
dc.date.available 2015-05-25T10:52:28Z
dc.date.issued 2014-03
dc.identifier.citation Mallajosyula, JK, Hiatt, E, Hume, S, Johnson, A, Jeevan, T, Chikwamba, R, Pogue GP, Bratcher, B, Haydon, H, Webby, RJ and McCormick, AA. 2014. Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge. Journal of Human Vaccines & Immunotherapeutics, vol. 10(3), pp 586-595 en_US
dc.identifier.issn 2164-5515
dc.identifier.uri http://hdl.handle.net/10204/7977
dc.description Copyright: 2014 Taylor & Francis. This is the pre-print/post-print version of the work. The definitive version is published in the Journal of Human Vaccines & Immunotherapeutics, vol. 10(3), pp 586-595. Due to copyright restrictions, the attached PDF file only contains the abstract of the full text item. For access to the full text item, please consult the publisher's website en_US
dc.description.abstract Recombinant subunit vaccines are an efficient strategy to meet the demands of a possible influenza pandemic, because of rapid and scalable production. However, vaccines made from recombinant hemagglutinin (HA) subunit protein are often of low potency, requiring high dose or boosting to generate a sustained immune response. We have improved the immunogenicity of a plant-made HA vaccine by chemical conjugation to the surface of the Tobacco mosaic virus (TMV) which is non infectious in mammals. We have previously shown that TMV is taken up by mammalian dendritic cells and is a highly effective antigen carrier. In this work, we tested several TMV-HA conjugation chemistries, and compared immunogenicity in mice as measured by anti-HA IgG titers and hemagglutination inhibition (HAI). Importantly, pre-existing immunity to TMV did not reduce initial or boosted titers. Further optimization included dosing with and without alum or oil-in water adjuvants. Surprisingly, we were able to stimulate potent immunogenicity and HAI titers with a single 15µg dose of HA as a TMV conjugate. We then evaluated the efficacy of the TMV-HA vaccine in a lethal virus challenge in mice. Our results show that a single dose of the TMV-HA conjugate vaccine is sufficient to generate 50% survival, or 100% survival with adjuvant, compared with 10% survival after vaccination with a commercially available H1N1 vaccine. TMV-HA is an effective dose-sparing influenza vaccine, using a single-step process to rapidly generate large quantities of highly effective flu vaccine from an otherwise low potency HA subunit protein. en_US
dc.language.iso en en_US
dc.publisher Taylor & Francis en_US
dc.relation.ispartofseries Workflow;13914
dc.subject Influenza en_US
dc.subject H1N1 vaccine en_US
dc.subject Plant made pharmaceuticals en_US
dc.subject HA subunit protein en_US
dc.subject Vaccination en_US
dc.subject Nanoparticles en_US
dc.subject Dose sparing en_US
dc.title Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ResearchSpace


Advanced Search

Browse

My Account